Oculis to Present Positive Phase 2 ACUITY Trial Results on Privosegtor for Acute Optic Neuritis
Oculis announced it will present phase 2 results for its investigational therapy Privosegtor (OCS-05) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress.
The late-breaking abstract, titled “Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial,” will be delivered by Céline Louapre, MD, PhD, of Pitié-Salpêtrière Hospital.
Session: Late Breaking Abstracts
Date/Time: Wednesday, September 24, 2025; 08:30 CET
The multicenter trial demonstrated that Privosegtor produced **clinically meaningful vision improvements—an average gain of 18 letters at 3 months—and preserved retinal structure while maintaining a favorable safety profile, according to Oculis. These findings support Privosegtor’s potential to provide neuroprotection not only in acute optic neuritis, but in broader neuro-ophthalmic and neurological indications.
“Oculis is proud to collaborate with Pitié-Salpêtrière Hospital on this landmark trial,” said Riad Sherif, MD, Chief Executive Officer of Oculis. “The ACUITY data highlight Privosegtor’s capacity to preserve retinal tissue and improve vision, reinforcing its promise as a novel therapy for multiple neuro-ophthalmic conditions. We look forward to advancing this candidate into new studies, including a program targeting MS relapses.”
“In acute optic neuritis, often an initial sign of MS or a frequent relapse type, Privosegtor showed strong neuroprotective effects, including retinal ganglion cell preservation and significant gains in low contrast visual acuity. These results open the door to transforming outcomes for patients experiencing acute MS relapses, Dr. Louapre said.
Privosegtor is a novel peptoid small molecule designed to deliver neuroprotection in optic neuritis and other neuro-ophthalmic diseases.